about
Microtubule-binding agents: a dynamic field of cancer therapeutics.Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptomsComparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis.Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancerIncidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey.Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.Novel microtubule-targeting agents - the epothilones.Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer.Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.Trends in neutropenia-related inpatient events.Docetaxel for the post-surgery treatment of patients with node-positive breast cancerBiological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.Targeting microtubules by natural agents for cancer therapy.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Dermatological adverse events with taxane chemotherapy.Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.Synergistic Anticancer Effect of Paclitaxel and Noscapine on Human Prostate Cancer Cell Lines.
P2860
Q27690249-FB0E9866-E749-41C5-91B4-9507D4C99CEFQ30478959-1C352432-ECC7-4313-A149-7AD8B459BB4EQ33395123-014C064A-413B-48E5-9BA8-A4A7AB6063F9Q33432594-B4CF51AF-A813-4A7E-A9FF-80D71B2E4BC6Q33605066-132E4F94-E175-4A13-851E-547ABB5D225FQ33756369-FA52F406-0DD2-446B-BE71-61F710D75CD7Q33851448-5AB63B45-3EFE-4BCD-AD3C-37BE74369767Q33886036-277363E4-6281-4724-BA9C-4F842CEF5585Q33932401-84147382-EFD5-45AA-BD9F-F9CE75BE36B3Q34001266-B527B2BE-EDBA-4C41-B63C-28C18C79B545Q34035471-2C5C0316-9FBC-415C-A272-1FF199F4D264Q34079286-78A2A998-5E1C-4E14-BF30-9A0D0F4E1245Q34611212-D5FF7634-BC7D-48F4-B09A-6466EA52A0A1Q34982543-C6D5015B-3853-4DA3-A909-0A7335310543Q35583734-63234AE5-B8F5-411C-9EA7-E4377ABB3B8FQ36072512-433B2EE0-D008-4FE1-9460-EDECF54A90D6Q36095153-464CD485-2CAC-4632-981C-170916D4E9D3Q36823602-9B926070-ABE3-4B3F-AD49-D789D030DE3CQ36920312-8C9B82C0-52B9-439E-AC89-93714954EE47Q37623838-D58ED5D0-8063-4BF6-80E8-C1B2A054953EQ37841631-B3C67863-D97B-4297-BE9E-FFE076673686Q38934447-F0F08B1D-9CD7-4AE6-B357-4EA3ED8642B4Q38968266-EAF25A19-E5EE-4E49-BFF3-D389E45F1EFCQ49166619-A416E00A-AC8C-4450-8F90-ED854286D7E7Q53701201-DB8B0326-98B8-458E-AAA4-E04F18A92A05
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Managing taxane toxicities.
@ast
Managing taxane toxicities.
@en
type
label
Managing taxane toxicities.
@ast
Managing taxane toxicities.
@en
prefLabel
Managing taxane toxicities.
@ast
Managing taxane toxicities.
@en
P1476
Managing taxane toxicities.
@en
P2093
Maurie Markman
P2888
P304
P356
10.1007/S00520-002-0405-9
P577
2002-10-15T00:00:00Z